CA2861402C - Stabilized aqueous antibody compositions - Google Patents

Stabilized aqueous antibody compositions Download PDF

Info

Publication number
CA2861402C
CA2861402C CA2861402A CA2861402A CA2861402C CA 2861402 C CA2861402 C CA 2861402C CA 2861402 A CA2861402 A CA 2861402A CA 2861402 A CA2861402 A CA 2861402A CA 2861402 C CA2861402 C CA 2861402C
Authority
CA
Canada
Prior art keywords
antibody
aqueous solution
protein
ethyleneimine
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861402A
Other languages
English (en)
French (fr)
Other versions
CA2861402A1 (en
Inventor
Guy Casy
Barry Kingston Derham
Jan Jezek
Nikki ROYLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of CA2861402A1 publication Critical patent/CA2861402A1/en
Application granted granted Critical
Publication of CA2861402C publication Critical patent/CA2861402C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CA2861402A 2012-01-30 2013-01-30 Stabilized aqueous antibody compositions Active CA2861402C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592323P 2012-01-30 2012-01-30
US61/592,323 2012-01-30
PCT/GB2013/050211 WO2013114112A2 (en) 2012-01-30 2013-01-30 Stabilized aqueous antibody compositions

Publications (2)

Publication Number Publication Date
CA2861402A1 CA2861402A1 (en) 2013-08-08
CA2861402C true CA2861402C (en) 2021-10-12

Family

ID=47681959

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861402A Active CA2861402C (en) 2012-01-30 2013-01-30 Stabilized aqueous antibody compositions

Country Status (9)

Country Link
US (2) US10532098B2 (https=)
EP (1) EP2809350B1 (https=)
JP (1) JP2015506369A (https=)
CN (1) CN104203282A (https=)
CA (1) CA2861402C (https=)
DK (1) DK2809350T3 (https=)
ES (1) ES2705538T3 (https=)
IN (1) IN2014DN06121A (https=)
WO (1) WO2013114112A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861402C (en) 2012-01-30 2021-10-12 Guy Casy Stabilized aqueous antibody compositions
BR112018016868B1 (pt) * 2016-02-19 2022-09-13 Avery Dennison Corporation Composições de adesivos e artigo compreendendo as mesmas
GB201613896D0 (en) 2016-08-12 2016-09-28 Arecor Ltd Novel composition
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CN112672734B (zh) * 2018-09-10 2023-04-11 陶氏环球技术有限责任公司 包含蛋白质和聚烷氧基脂肪酰基表面活性剂的组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
DE19726186A1 (de) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
DE19933024C2 (de) 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Kationische Blockcopolymere
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
ATE517926T1 (de) * 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
AU2004260935A1 (en) 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
US7022214B2 (en) * 2004-01-21 2006-04-04 Bio-Rad Laboratories, Inc. Carrier ampholytes of high pH range
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
WO2007133812A2 (en) 2005-12-30 2007-11-22 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US20080312174A1 (en) 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
MX2011003074A (es) 2008-09-24 2011-04-19 Stabilitech Ltd Metodo para conservar polipeptidos utilizando un azucar y polietilenimina.
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
CA2861402C (en) 2012-01-30 2021-10-12 Guy Casy Stabilized aqueous antibody compositions

Also Published As

Publication number Publication date
WO2013114112A3 (en) 2013-11-07
EP2809350B1 (en) 2018-10-17
IN2014DN06121A (https=) 2015-08-14
CA2861402A1 (en) 2013-08-08
EP2809350A2 (en) 2014-12-10
US20200138946A1 (en) 2020-05-07
ES2705538T3 (es) 2019-03-25
US20150010548A1 (en) 2015-01-08
US10532098B2 (en) 2020-01-14
US12016922B2 (en) 2024-06-25
CN104203282A (zh) 2014-12-10
DK2809350T3 (en) 2019-01-28
JP2015506369A (ja) 2015-03-02
WO2013114112A2 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
US12016922B2 (en) Stabilized aqueous antibody compositions
US12600763B2 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
US10899841B2 (en) Anti-BAFFR antibody formulations and methods of use thereof
EP2598167B1 (en) Stabilized aqueous antibody compositions
JP7278952B2 (ja) 安定化された抗体タンパク質溶液
EP3585360B1 (en) Stabilized antibody solutions
US20240270864A1 (en) Compositions and methods for injecting particle suspensions
US20200069799A1 (en) Stabilized antibody protein solutions
AU2020245573B2 (en) Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
WO2026080887A2 (en) Cd-40 targeting compositions and uses thereof
US20230414753A1 (en) Stabilized antibody protein solutions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180111

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250122

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250122

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251229